Risk of upper gastrointestinal complications associated with cyclooxygenase-2 selective and nonselective nonsteroidal antiinflammatory drugs

Pharmacotherapy

Volumn 29, Issue 12, 2009, Pages 1397-1407

  Castellsague, Jordi ^a   Holick, Crystal N ^b   Hoffman, Clorinda C ^b   Gimeno, Victoria ^a   Stang, Mary Rose ^c   Perez Gutthann, Susana ^a  

^a PFIZER INC   (United States)

^b i3 Drug Safety   (United States)

^c Saskatchewan Health   (Canada)

Author keywords

COX 2; Cyclooxygenase 2; Gastrointestinal complications; Nonsteroidal antiinflammatory drug; NSAID

Indexed keywords

ARTHROTEC; CELECOXIB; DICLOFENAC; IBUPROFEN; INDOMETACIN; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; ROFECOXIB;

ADULT; AGED; ARTICLE; CANADA; CASE CONTROL STUDY; CLINICAL EVALUATION; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE ASSOCIATION; DOSE RESPONSE; FEMALE; FOLLOW UP; GASTROINTESTINAL OBSTRUCTION; HIGH RISK PATIENT; HUMAN; INTESTINE PERFORATION; INTESTINE ULCER; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; OSTEOARTHRITIS; PEPTIC ULCER BLEEDING; PRESCRIPTION; PUBLIC HEALTH INSURANCE; RHEUMATOID ARTHRITIS; TREATMENT DURATION;

ADULT; AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CASE-CONTROL STUDIES; CYCLOOXYGENASE 2 INHIBITORS; DATABASES, FACTUAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; GASTROINTESTINAL DISEASES; HOSPITALIZATION; HUMANS; LACTONES; LOGISTIC MODELS; MALE; MIDDLE AGED; PYRAZOLES; RISK; SASKATCHEWAN; SULFONAMIDES; SULFONES; YOUNG ADULT;

EID: 73349142682     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.29.12.1397     Document Type: Article

References (17)

1. . Bombardier C, Laine L, Reicin A, et al, for the VIGOR Study Group. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 2000;343:1520-8.
2. . Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the celecoxib long-term arthritis safety study (CLASS): a randomized controlled trial. JAMA 2000;284:1247-55.
3. . Mamdani M, Rochon PA, Juurlink DN, et al. Observational study of upper gastrointestinal haemorrhage in elderly patients given selective cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs [published online ahead of print September 21, 2002]. BMJ 2002;325:624. Available from http://dx.doi.org/10.1136/bmj.325.7365.624.
4. . Hippisley-Cox J, Coupland C, Logan R. Risk of adverse gastrointestinal outcomes in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population-based nested case-control analysis. BMJ 2005;331:1310-16.
5. . Lanas A, Garcia-Rodriguez LA, Arroyo MT, et al. Risk of upper gastrointestinal ulcer bleeding associated with selective cyclooxygenase-2 inhibitors, traditional non-aspirin non-steroidal anti-inflammatory drugs, aspirin and combinations. Gut 2006;55:1731-8.
6. . Laporte JR, Ibanez L, Vidal X, Vendrell L, Leone R. Upper gastrointestinal bleeding associated with the use of NSAIDs: newer versus older agents. Drug Saf 2004;27:411-20.
7. . Bresalier RS, Sandler RS, Quan H, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005;352:1092-102.
8. . Solomon SD, Pfeffer MA, McMurray JJ, et al. Effect of celecoxib on cardiovascular events and blood pressure in two trials for the prevention of colorectal adenomas. Circulation 2006;114:1028-35.
9. . Hernandez-Diaz S, Varas-Lorenzo C, Garcia Rodriguez LA. Non-steroidal antiinflammatory drugs and the risk of acute myocardial infarction. Basic Clin Pharmacol Toxicol 2006;98:266-74.
10. . McGettigan P, Henry D. Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. JAMA 2006;296:1633-44.
11. . Downey W, Stang M, Beck P, Osei W, Nichol J. Health services databases in Saskatchewan. In: Strom B, ed. Pharmaco-epidemiology. Chichester, England: John Wiley and Sons Ltd., 2005:295-310.
12. . Raiford DS, Perez Gutthann S, Garcia Rodriguez LA. Positive predictive value of ICD-9 codes in the identification of cases of complicated peptic ulcer disease in the Saskatchewan hospital automated database. Epidemiology 1996;7:101-4.
13. . Gimeno V, Bernat M, Stang MR, Aguado J, Castellsague J, Perez-Gutthann S. Validity of ICD-9 codes for upper gastrointestinal bleeding in the Saskatchewan Health databases. Pharmacoepidemiol Drug Saf 2006;15:S231-2.
14. . Rothman KJ, Greenland S. Stratified analysis. In: Rothman KJ, ed. Modern epidemiology. Boston: Little Brown;1986:220-36.
15. . Gutthann SP, Garcia Rodriguez LA, Raiford DS. Individual nonsteroidal antiinflammatory drugs and other risk factors for upper gastrointestinal bleeding and perforation. Epidemiology 1997;8:18-24.
16. . Garcia Rodriguez LA, Tacconelli S, Patrignani P. Role of dose potency in the prediction of risk of myocardial infarction associated with nonsteroidal anti-inflammatory drugs in the general population. J Am Coll Cardiol 2008;52:1628-36.
17. . MacDonald TM, Morant SV, Goldstein JL, Burke TA, Pettitt D. Channelling bias and the incidence of gastrointestinal haemorrhage in users of meloxicam, coxibs, and older, non-specific non-steroidal anti-inflammatory drugs. Gut 2003;52:1265-70.